I mprovements in donor selection, infectious disease testing, and donor deferral policies have effectively reduced but not eliminated the risk of transfusiontransmitted infectious disease (TTID). The risk persists due to undetected low titers of recognized agents during the infectious window period and the emergence of novel pathogens such as Babesia, dengue, chikungunya, and Zika viruses (ZIKVs), [1] [2] [3] [4] which may persist in cellular components where they are undetectable by conventional nucleic acid testing. 5 Emerging pathogens are not predictable and may be present in the blood donor population for a period of time before discovery and there are limits to the level of sensitivity achievable with testing, especially early after initial infection. 6, 7 US Food and Drug Administration (FDA)-approved tests are not available for many agents known to contaminate blood (e.g., Babesia microti
4
) and, finally, bacterial contamination remains a concern for red blood cells (RBCs). 8, 9 The risk of TTID is compounded by the cumulative exposure that many patients experience with chronic transfusion support. 6 In addition, patients at risk for transfusion-associated graft-versus-host disease (GVHD) may not be recognized and consequently fail to receive irradiated blood products when these are selectively prescribed. 10 An alternative proactive approach to reduce the risk of TTID and transfusion-associated GVHD is pathogen reduction treatment of blood components targeted to nucleic acids. Currently, pathogen reduction treatment platelet (PLT) and plasma products prepared with amotosalen and ultraviolet A light technology (INTERCEPT Blood System, Cerus Corporation) are licensed for use in the United States and in many other countries. 11, 12 A pathogen reduction technology using a reactive small molecule (amustaline, S-303) and glutathione (GSH) is in clinical development (Fig. 1) . 13 Amustaline irreversibly forms adducts on, and crosslinks DNA and RNA, preventing replication of infectious pathogens and white blood cells (WBCs). RBCs treated with a first-generation process were evaluated for safety and efficacy in Phase III clinical trials 14, 15 and the system exhibited effective in vitro inactivation of multiple blood-borne pathogens (4 log) and residual WBCs. 13, 16, 17 Low-titer antibodies to amustaline-treated RBCs were identified in two patients participating in a chronic transfusion clinical trial 15 and were found to be specific for the acridine moiety of amustaline. Although the antibodies did not cause clinical hemolysis nor support in vitro phagocytosis of sensitized RBCs, the amustaline treatment process was modified to reduce reactivity with the RBC cell surface to lower the potential for immune responses. 13 In a Phase II clinical trial in healthy volunteers, second-generation amustalinetreated RBCs met FDA criteria for posttransfusion recovery and were shown to be metabolically and physiologically sufficient for transfusion following 35 days of storage. 18, 19 Inactivation of pathogens and WBCs is conserved with the higher GSH concentration, resulting in broad and efficient inactivation with the modified process. The primary objective of this study (named "STARS") was to assess the characteristics of S-303-treated RBCs in a Phase III device study to meet European regulatory requirements for Conformit e Europ eene (CE) mark certification and to evaluate safety and efficacy in support of acute anemia in patients undergoing cardiac surgery using exploratory endpoints. A secondary objective was hypothesis generation for endpoints informative of tissue oxygenation to be used in a subsequent powered Phase III clinical efficacy study.
MATERIALS AND METHODS

Trial design and study population
This was a randomized, controlled, double-blind, parallelgroup, multicenter study performed at the German Red Cross Blood Donor Service (GRCBDS; DRKBlutspendedienst Baden Wuerttemberg-Hessen, Germany), the Johann Wolfgang Goethe University Hospital in Frankfurt, and the Kerckhoff-Klinik in Bad Nauheim. The trial was approved by the ethics committees of all participating institutions. Study patients, treating physicians, patient caregivers, clinical study personnel, clinical investigators, and sponsor personnel were blinded to treatment assignment. Blood center personnel involved in processing, testing, and distribution of RBCs were not blinded.
Study RBCs
Blood donors were screened and qualified according to the German "Guidelines for the Collection of Blood and Blood Components and for the Use of Blood Products." 20, 21 Leukoreduced RBCs in the additive solution SAG-M were derived from buffy coat-depleted whole blood collections with a volume of 220 to 340 mL. Control RBCs were transferred to an identical storage bag for the purpose of blinding and test RBCs were treated with the amustaline process as previously described (Fig. 1) . 13 Test
RBCs were mixed with a processing solution containing GSH, followed by amustaline (20 mmol/L GSH-0.2 mmol/ L amustaline, based on 280-mL RBC input 
Quality control (QC) data on study RBCs
Study RBCs were evaluated PP and after 35 to 38 days for untransfused components. Variables assessed included Hb content, hematocrit (Hct), hemolysis, normalized adenosine triphosphate (ATP), plasma-free Hb, mean corpuscular volume (MCV), mean corpuscular Hb concentration (MCHC), pH, extracellular potassium, glucose, lactate, residual plasma protein, and sterility. Test RBCs were analyzed for the primary degradation products of amustaline: acridine (S-300), 9-glutathiyl acridine, 9-(amino glutathione)-acridine [9A-GSH], 9-(amino glutathione disulfide)-acridine [9A-GSSG]), and GSH (GSH/glutathione disulfide [GSSG] ). Degradation products were measured using highperformance liquid chromatography.
Clinical study population
The clinical study population included adults (18 years old) scheduled to undergo elective coronary artery bypass graft (CABG) only (first procedure), valve repair or replacement only (first procedure), or a combination of first-time CABG and valve repair or replacement. Only patients with a high likelihood of receiving a RBC transfusion, as determined by a transfusion risk understanding scoring tool (TRUST) score of at least 3, were enrolled. 22 Patients and their treating physicians were blinded as to the randomization.
To reduce the number of RBCs discarded and to prevent extensive use of D-RBCs, only group O D1 and group A D1 patients were enrolled. Patients requiring gamma irradiation of blood products were excluded. Further exclusion criteria included active autoimmune hemolytic anemia or a positive direct antiglobulin test (DAT), pregnancy, renal failure (creatinine level, >1.8 mg/dL) within 7 days before surgery, existing cross-reactive antibodies to amustaline-treated RBCs identified by gel card assay with paired amustaline-treated and untreated RBC cell panels, or an emergency or salvage surgical procedure. Written informed consent was obtained from all study subjects before screening.
Transfusion strategies
Blood transfusions were ordered according to the national German and local institutional guidelines for therapy with blood components and plasma derivatives. 21 
Randomization
The randomization assignments were generated by an interactive Web response system and provided to the blood center by a contract research organization (Nextrials). Patients were randomized based on a stratified scheme that included the clinical site and elective cardiac procedure (simple valve or CABG vs. complex procedure).
Randomized patients who did not require any RBC transfusions were replaced and excluded from analysis. Randomized and transfused patients comprised the modifiedintention-to-treat (MITT) population.
Endpoints
As this study was focused on supporting CE mark certification for the investigational device, the primary and secondary endpoints were selected to demonstrate quality of amustaline-treated RBCs compared to conventional RBCs. PP RBC Hb content was selected as the primary endpoint because it is reasonably expected to be proportional to the posttransfusion Hb increment in nonbleeding patients, although not necessarily so in actively bleeding surgical patients in which it is not feasible to measure Hb increments. The viability of amustaline-treated RBCs characterized by posttransfusion recovery has been established by prior radiolabeling studies. 18, 19 The secondary endpoints included proportion of RBCs that met European Directorate for the Quality of Medicines (EDQM) guidelines for Hb content, Hct, and hemolysis at the EOS; the proportion of RBCs that had adenosine triphosphate (ATP) levels of more than 2 mmol/L; and the proportion of RBCs that had plasma-free Hb of less than 0.8% of the total Hb mass.
The clinical safety and efficacy of amustalinetreated RBCs was assessed by measuring RBC usage and by evaluating adverse events (AEs) and exploratory clinical outcomes reflective of tissue oxygenation. The exploratory outcome of interest was renal insufficiency defined as serum creatinine level of more than 2 mg/ dL with at least a 50% increase from preoperative baseline and/or a new requirement for renal replacement therapy (i.e., dialysis). The study also evaluated hepatic insufficiency defined as total bilirubin that is more than two times the upper limit of normal and at least a 50% increase from the preoperative baseline and global cardiovascular function as assessed by the 6-minute walk test [6MWT] . 23 Clinical data were collected from the day of surgery through Day 13 postsurgery or death or discharge from hospital whichever occurred first. Baseline, follow-up (Days 28-40), and end-of-study (Day 90) blood samples were screened at the GRCBDS for RBC alloantibodies using standard indirect antiglobulin tests (IATs) as well as DAT gel card assays and for amustaline antibodies with a screening panel that consisted of 3 group O RBC units with or without amustaline treatment. To evaluate amustaline-specific antibodies in the presence of antibodies to intrinsic RBC alloantigens, an additional panel of up to six alloantigen-characterized, corresponding amustaline-treated and untreated RBCs were available for testing.
Data safety monitoring board
A data safety monitoring board (DSMB) reviewed grouped, blinded study data after half of the patients had been transfused. No data safety monitoring board safety concerns were raised.
Sample size calculation
A minimum of 400 RBC units (200 for each treatment arm) were required to demonstrate equivalence between the mean Hb content of test and control components with 97.8% power at the 5% significance level, based on an equivalence margin of 65 g/RBCs for the mean treatment difference. For the exploratory clinical assessments, a minimum of 50 cardiovascular surgery patients that received at least one study transfusion were evaluated to assess the clinical and safety endpoints. The study was not powered to detect differences in the exploratory endpoints, but was used for hypothesis generation to identify potential endpoints for a subsequent Phase III study powered for clinical efficacy.
Statistical analysis
The primary efficacy analysis assessed the mean treatment difference (test -control) in PP Hb content from all RBCs using an equivalence design. A fixed-effects analysis of covariance (ANCOVA) model was used while controlling for potential confounders including the sex, donor blood group (group O vs. non-O), and RBC volume and Hct. Equivalence was declared at the 5% significance level if the two-sided 95% confidence interval (CI) for the mean treatment difference (test -control) was within the equivalence margins of 65 g/unit.
The exploratory clinical endpoints were analyzed using the MITT group. The proportion of patients experiencing renal insufficiency or hepatic insufficiency was compared using a Cochran-Mantel-Haenszel (CMH) test (controlling for the site and surgical procedure performed). The 6MWT was compared using analysis of variance (ANOVA; controlling for the site and surgical procedure). The physical mobility assessment performed before the 6MWT was measured using the Walking Impairment Questionnaire. Walking Impairment Questionnaire total scores were calculated. Summaries for the frequency of all serious, related, and severe (grade 3) TEAEs were reported by treatment group, system organ class, and preferred term (PT). All other quantitative safety data were summarized descriptively. A p value of less than 0.05 was considered significant. Statistical analysis used computer software (Statistical Analysis System, SAS Institute, Inc.).
RESULTS
RBC production and in vitro assessment
A total of 774 study RBC units were manufactured, 659 were released into clinical inventory, and 148 were transfused (Fig. 2) 
QC data on study RBCs
All variables, except PP Hct, were significantly different between test and control RBCs for at least one time point (Table S1 , available as supporting information in the online version of this paper). MCHC (PP and EOS) and glucose (EOS) were higher in test compared to control (p < 0.05; Table S1), while MCV (PP and EOS), pH (EOS), potassium (EOS), lactate (EOS), and residual plasma protein (EOS) were lower (p < 0.05). These differences were not considered to be of physiologic or clinical significance. EOS residual plasma protein was 3.4 6 1.4-fold lower in test compared to control (Table 1 ; p < 0.05). All test and control RBCs were culture negative (no growth of bacteria) at EOS.
Test RBCs had a mean PP S-300 (the primary degradation product) level of 18.4 6 3.4 mmol/L (range, 9.6-35.5 mmol/L). PP extracellular mean GSH levels were 5.3 6 0.8 mmol/L in test RBCs. GSSG PP was below the limit of quantitation, 0.75 mmol/L, for both treatment groups. Despite a decrease in GSH over storage, the level of GSSG remained less than 0.75 mmol/L (the limit of quantitation) in test RBCs at EOS. The mean level of 9-glutathiyl acridine of test RBCs at EOS was 3.2 6 1.1 mmol/L (range, <1-6.5 mmol/L) and the mean level of 9A-GSH at EOS was 4.1 6 1.1 mmol/L (range, 1-7.5 mmol/L). 9A-GSSG was below the limit of quantitation (1.0 mmol/L) in all PP and EOS test components. The levels of these reaction byproducts were consistent with the high safety margins established in preclinical studies. 24 
Clinical endpoints
Eighty-seven patients were randomly assigned and 51 received study RBCs, comprising the MITT population (Fig. 3) . None of the patients screened for enrollment had existing cross-reactive antibodies to S-303 RBCs. The 51 transfused patients were equally distributed between the test and control groups in terms of demographics and surgical characteristics; however, test patients had significantly higher serum creatinine levels at baseline (mean serum creatinine, 1.12 mg/dL vs. 0.95 mg/dL, p 5 0.033; Table 2 ). The proportion of MITT patients with abnormal serum creatinine levels at baseline was significantly higher for test ( At transfusion, the mean storage age of the study RBCs before transfusion was 18.9 days ( 6 8.4), with no difference between treatment groups (p 5 0.253). There were no differences between treatment groups in the mean number or in the mean volume of study RBCs transfused (Table 3) . Three (12.0%) test and four (15.4%) control patients received off-protocol RBCs due to excessive urgent demand for RBCs transfusions. Although not statistically different, there were numerical differences between treatment arms in the exposure to other blood components ( Table 3) that were explained by an outlier patient in the test arm who received 21 Hct components (6.83 L) and 5.29 L of plasma for treatment of an aortic dissection with intraoperative bleeding resulting in death due to uncontrolled hemorrhage after surgery.
Clinical safety and efficacy
The overall incidence of renal insufficiency was 15.7% and there was no significant difference between the treatment groups (p 5 0.41; Table 4 ). None of the renal insufficiency events occurred in relationship to an acute decrease in Hb levels or administration of study RBCs and a correlation of the effect of transfusion to renal organ perfusion could not be established. Renal insufficiency resolved in five of the eight patients (test, four; control, one). The incidence of hepatic insufficiency was low (2%), with no detectable difference between treatment groups (p 5 0.37). Thirtyseven of 51 patients (73%) were able to perform the 6MWT at the time of first ambulation. There were no differences between treatment groups in the mean distance walked in meters between Day 0 and 6 or on Day 13 or discharge (Table 4) .
Most patients in both groups (84.3%) experienced an AE (Table 5 ). There were no statistical differences in the overall incidence of AEs, or in possibly related AEs, although there was a trend toward more severe AEs (p 5 0.07) in the test group. No trend in serious AEs was apparent when examined by system organ class. * p values and 95% CIs for the mean treatment difference (test -control) are based on the following: 1) analysis of covariance model controlling for the treatment, sex, blood type, input Hct, and input volume for all assays other than residual plasma protein and 2) t test with unequal variances for the residual plasma protein assay. † Equivalence was declared at the 5% significance level if the two-sided 95% CI for the mean treatment difference (test -control) was within the equivalence (noninferiority) margins of 65 g/unit.
on Day 16). Although a relationship to study RBCs of the myocardial infarction was not ruled out, assessment of relatedness was complicated by proximity to the surgery, the subject's medical history, the use of catecholamines, and the fact that the patient continued receiving transfusion support with study RBCs without additional cardiac SAEs.
No transfusion reactions or hemolytic events were reported. Five patients died during this study with the following causes of death: three test patients (ventricular fibrillation on Day 26 postsurgery, hemorrhage during surgery, and multiorgan failure on Day 2 postsurgery) and two control patients (septic shock on Day 53 postsurgery and multiorgan failure on Day 4 postsurgery). The deaths were not considered related to the administration of study RBCs. All of these events were related to the patients' primary disease, comorbid conditions, and/ or postsurgical complications unrelated to RBC transfusion exposure.
Two test patients with a negative DAT at baseline con- 
DISCUSSION
The results of this Phase III device trial demonstrate that amustaline-treated RBCs retained Hb content equivalent to that observed in conventional RBCs and met EDQM guidelines for Hb content, Hct, and plasma-free Hb when produced for clinical use. When transfused to cardiac surgery patients, no treatment differences were observed in usage of RBCs to support acute anemia or in clinical outcomes indicative of insufficient tissue oxygenation, such as renal or hepatic failure, although this study was not powered to differentiate these exploratory clinical endpoints. Renal insufficiency was more correlated to surgical complications during complex cardiac surgery, with random distribution between the test and control groups. The overall incidence (15.7%) was consistent with the incidence for renal failure reported in comparable patient populations and in a prior study utilizing a firstgeneration version of the amustaline RBC treatment process. 15, [25] [26] [27] To explore the value of renal injury as a potential endpoint informative for tissue oxygenation in a subsequent powered clinical efficacy study, post hoc reanalyses of the serum creatinine levels and the proportions of patients with abnormal serum creatinine levels at baseline were conducted. Acute kidney injury (AKI) is recognized as a sensitive prognostic indicator in critically ill, including cardiac surgery patients. 26, [28] [29] [30] [31] Using the KDIGO definition of AKI 32 we observed an overall rate of 31.4% (test 11 (44%) vs. control five (19.2%); p 5 0.11), suggesting that this might be an appropriate primary endpoint on which to power a pivotal Phase III clinical trial. A baseline difference in serum creatinine levels ( Table 2 ) and in the proportion of patients with abnormal baseline serum creatinine concentrations, a known risk factor for AKI, was noted; 14 of 25 test patients had serum creatinine concentrations above normal reference ranges at baseline versus four of 26 control patients (p 5 0.003; data not shown). Baseline renal status must be considered as a covariate when using AKI as a clinical endpoint in this patient population. We included the 6MWT as an exploratory endpoint. 33, 34 Thirty-seven of 51 (72.6%) enrolled patients were assessed on Days 0 to 6 and 32 of 51 (62.7%) patients were available for assessment on the day of discharge or Day 13 postsurgery, whichever occurred first. Failure to assess 6MWT was due to patient withdrawal from study (five patients), death (five patients), patient discharge to local/regional facilities before they could ambulate, or patient inability to perform the test (Fig. 3) . The variable clinical condition of patients in the immediate postoperative period and the variable date of discharge and/or death after surgery contributed to missing data in approximately one-third of the participants. For all patients evaluated there was no difference between groups, but the standard deviation (SD) was broad (50%-60% of the mean value), suggesting that the 6MWT had limited power for detecting differences between test and control subjects at these time points. Taken together, we conclude that the 6MWT is not an informative indicator of RBC function for future studies of pathogen-inactivated RBCs immediately after cardiac surgery. While it has been utilized during cardiac rehabilitation to assess patient recovery over a longer time period, it is unlikely that an assessment performed during rehabilitation weeks after RBC transfusion 34 when few transfused RBCs remain in the circulation could be related to functional RBC differences. Observed AEs were within the expected spectrum of comorbidity and mortality for patients of similar age undergoing cardiovascular surgery requiring RBC transfusion. 15, 35 Cardiac rhythm disturbances requiring treatment (Grade 3) are common after cardiac surgery. 36, 37 Pleural effusions and delirium are among the most common side effects after CABG and valve replacement surgery with reported incidences of up to 90% and 3% to 73%, respectively. 38, 39 Due to the limited number of patients enrolled, further investigation on possible adverse effects and Hb increment after transfusion of amustaline-treated RBCs is required in nonsurgical patients to evaluate further the safety end efficacy of this novel blood product. The clinical data from this study are consistent with the data from a prior clinical trial utilizing a previous version of the system with amustaline, where amustaline-treated RBCs and conventional RBCs were equivalent with respect to clinical efficacy and safety in supporting the transfusion needs of cardiac surgery patients. 15 The data suggest that the storage lesion in amustaline-treated RBCs is comparable, if not minimized, relative to that in conventional RBCs. Substantially reduced residual plasma protein levels resulted from the suspension media exchange step incorporated into the amustaline treatment process. This may reduce transfusion reactions to plasma proteins and could improve patient safety, due to lower levels of HLA antibodies implicated in TRALI that are correlated with the volume of transfused plasma. 40 Levels of degradation products of amustaline and GSH were consistent with previous observations (unpublished data) and within the safety margins derived from preclinical testing. 24 New and emergent pathogens such as the ZIKV underscore the need for a sustainable and proactive approach to reduce the risk of TTID. 2 Given the proven potential to be transmitted by transfusion 41, 42 and its association with deleterious outcomes such as microcephaly 43, 44 and Guillain-Barre syndrome, 45 the FDA recently issued a final guidance recommending the cessation of blood collections in areas with active transmission of ZIKV, such as Puerto Rico; investigational ZIKV tests; or the use of an approved pathogen reduction device for plasma and for Hct. The guidance specifically states that pathogen reduction systems for RBCs may replace testing, once clinically available, indicating the FDA's commitment to pathogen reduction as a future risk mitigation intervention for RBC safety. 46 This trial successfully demonstrated that amustalinetreated RBCs were equivalent to conventional RBCs in terms of Hb content and other in vitro variables correlated with transfusion efficacy. Amustaline-treated RBCs supported patients as effectively as conventional RBCs in the setting of RBC transfusion for acute anemia during cardiac surgery with hemodynamic changes, and the safety profile was comparable given the limited data set. There was no difference in RBC usage between treatment groups, indicative of adequate tissue oxygenation after transfusion of test RBCs.
The study confirmed that AKI may be an informative endpoint and that baseline serum creatinine is an important covariate that must be considered. In conclusion, amustaline-treated RBCs were well tolerated justifying larger Phase III clinical trials to confirm clinical efficacy and safety.
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